Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
37 USD | +0.19% | +3.44% | +71.93% |
Financials (USD)
Sales 2024 * | 450K | Sales 2025 * | 500K | Capitalization | 1.49B |
---|---|---|---|---|---|
Net income 2024 * | -174M | Net income 2025 * | -193M | EV / Sales 2024 * | 1,895 x |
Net cash position 2024 * | 638M | Net cash position 2025 * | 333M | EV / Sales 2025 * | 2,314 x |
P/E ratio 2024 * |
-8.84
x | P/E ratio 2025 * |
-10.3
x | Employees | 30 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 88.57% |
Latest transcript on Spyre Therapeutics, Inc.
1 day | +0.19% | ||
1 week | +3.44% | ||
Current month | +12.02% | ||
1 month | -1.31% | ||
3 months | +64.70% | ||
6 months | +263.46% | ||
Current year | +71.93% |
Managers | Title | Age | Since |
---|---|---|---|
Cameron Turtle
CEO | Chief Executive Officer | 34 | 23-06-21 |
Scott Burrows
DFI | Director of Finance/CFO | 47 | 23-08-31 |
Brian Connolly
CTO | Chief Tech/Sci/R&D Officer | - | Nov. 26 |
Members of the board | Title | Age | Since |
---|---|---|---|
Tomas Kiselak
BRD | Director/Board Member | 38 | 23-06-21 |
Russell Cox
CHM | Chairman | 60 | 15-05-31 |
Jeffrey Albers
BRD | Director/Board Member | 52 | Nov. 26 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-13 | 37 | +0.19% | 274,679 |
24-05-10 | 36.93 | +4.94% | 429,293 |
24-05-09 | 35.19 | +6.57% | 185,724 |
24-05-08 | 33.02 | -3.56% | 245,077 |
24-05-07 | 34.24 | -4.28% | 186,999 |
Delayed Quote Nasdaq, May 13, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+71.93% | 1.49B | |
+5.66% | 111B | |
+11.23% | 105B | |
-0.38% | 21.93B | |
-12.15% | 22.34B | |
-7.66% | 18.59B | |
-36.52% | 18.12B | |
-10.09% | 16.96B | |
+3.33% | 13.7B | |
+36.58% | 12.45B |
- Stock Market
- Equities
- SYRE Stock